Published in Biotech Business Week, January 8th, 2007
The observed preliminary objective response rates have met the predefined criteria for expansion of the CTCL arm of the trial. The predefined criteria in the protocol required at least 2 objective responses be observed in the first 13 patients treated. The trial will now enroll up to a total of 34 patients with CTCL to further evaluate the single agent activity of intravenous belinostat (PXD101) for the treatment of this...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.